Search

Abstract: In the present study, we investigated growth, development and viability at the larval, juvenile and adult stages of Strongylocentrouts nudus (Sn), Strongylocentrotus intermedius (Si), Anthocidaris crassispina (Ac) and their hybrids. We achieved improvements of traits related to growth in hybrid F1 via hybridization among the three commercially important sea urchins in China. The obtained results reveal that the average performance traits from fertilization to the 3-month-old juvenile stage (i.e., fertilization rate, larval survival rate, metamorphosis, juvenile survival rate) of heterospecific crosses were significantly inferior to those of conspecific crosses. After 22 months of lab culturing, we measured the growth characteristics (i.e., diameter, height, wet body weight and gonad weight) and evaluated heterosis. The Si×Ac group showed clear heterosis in all characteristics compared to conspecific controls (4.00–59.40%). The Si×Sn and Ac×Sn groups showed limited heterosis, and the hybrids produced few or no gametes. The heterosis of Si×Ac, Si×Sn and Ac×Sn obtained in this work will have significant implications for the development of sea urchin aquaculture. [Copyright &y& Elsevier]

Objectives: The aim of the present report was to compare 2-year safety outcomes of two biodegradable polymer (BP) sirolimus-eluting stents (SESs) with different drug eluting and polymer absorption kinetics in a subgroup of complex patients and lesions., Background: The previously published PANDA III study showed the BuMA BP SES, with faster drug elution and polymer absorption, was non-inferior to the Excel SES in target lesion failure (TLF)., Methods: In PANDA III trial, patients who fulfilled one or more of the following criteria were included: Small vessel disease (reference vessel diameter ≤ 2.5 mm); long lesion (lesion length ≥ 20 mm); chronic total occlusion lesion; and diabetic patients., Results: Among 2,348 patients randomly assigned to treatment with BuMA (n = 1,174) or Excel SES (n = 1,174) in the PANDA III study, 858 in the BuMA group and 855 in the Excel group satisfied the inclusion criteria. At 2-year follow-up, the incidence of definite/probable stent thrombosis (ST) was significantly lower with BuMA SES as compared with Excel SES (0.7% vs. 1.9%, p = 0.03). This difference was mainly caused by decreased subacute stent thrombosis rate (0% vs. 0.6%, p = 0.03). In patients who did not fulfill the complex patient and lesion criteria, there were no between-group difference in ST (0.7% vs. 0%, p = 0.50). Myocardial infarction and TLF rates were similar (5.7% vs. 6.0%, p = 0.79 and 8.8% vs. 7.5%, p = 0.34, respectively), whereas patient-oriented composite endpoint was higher with BuMA SES mainly due to high risk of revascularization (15.6% vs. 11.4%, p = 0.01; 8.4% vs. 4.6%, p < 0.01)., Conclusions: Two-year subgroup analysis of the all-comer PANDA III trial revealed the increased safety benefit of the BuMA SES is more prominently seen in complex patient and lesion population., Clinical Trial: ClinicalTrial.gov, Identifier-NCT02017275., (© 2019 Wiley Periodicals, Inc.)

Background: The aim of this study was to investigate the safety and efficacy of dalteparin during an elective percutaneous coronary intervention (PCI) procedure in a large cohort., Materials and Methods: In this prospective, randomized, open-label design study, 733 patients undergoing elective PCI were divided into an unfractionated heparin group (group 1, 323 patients) or a dalteparin group (group 2, 410 patients). Blood samples were collected before and 18-24 h after the PCI procedure to determine the serum levels of cardiac troponin I (cTnI) and creatine kinase isoenzyme MB. Major adverse cardiac events (MACEs) and bleeding events during hospitalization were also recorded. Patients with an increased level of serum cTnI before PCI were excluded from the study., Results: After PCI, the cTnI values were greater than three times the upper limit of normal in 43 cases (13.3%) in group 1 and 52 cases (12.7%) in group 2, without a statistically significant difference between the two groups (P=0.801). An increased creatine kinase isoenzyme MB level of greater than two times the upper limit of normal was found in 10 cases (3.1%) in group 1 and 12 cases (2.9%) in group 2, without a statistically significant difference between the two groups (P=0.894). Postoperative bleeding was observed in nine patients (2.8%) in group 1 and six patients (1.5%) in group 2. Postoperative MACEs were observed in two patients (0.6%) in group 1 and two patients (0.5%) in group 2. There were no significant differences between the two groups with respect to bleeding events or MACEs., Conclusion: Our study showed that dalteparin might be as effective and safe as unfractionated heparin for anticoagulation during elective PCI.